行情

CBIO

CBIO

Brookfield再生能源
NASDAQ

实时行情|Nasdaq Last Sale

5.05
+0.69
+15.76%
交易中 15:18 04/08 EDT
开盘
4.470
昨收
4.360
最高
5.09
最低
4.440
成交量
17.52万
成交额
--
52周最高
10.78
52周最低
3.430
市值
8,401.42万
市盈率(TTM)
-1.0979
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CBIO价格均价为21.00,最高价位23.00,最低价为20.00。

EPS

CBIO 新闻

更多
  • 美联储会议纪要:经济前景面临“极大程度”不确定性
  • 新浪美股 · 1小时前
  • 经济复苏为时尚早 全球市场持续震荡 欧股收盘走低
  • 新浪财经综合 · 1小时前
  • 调查:四分之一的美国人因疫情封锁措施失业或减薪
  • 新浪美股 · 1小时前
  • 美国调查丨快递小哥不干了!
  • 央视 · 2小时前

所属板块

生物技术和医学研究
+3.18%
制药与医学研究
+3.12%

热门股票

代码
价格
涨跌幅

CBIO 简况

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
展开

微牛提供Catalyst Biosciences Inc(NASDAQ-CBIO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CBIO股票新闻,以帮助您做出投资决策。